Mira
Mira (Quanovate Tech Inc.) is a US women's health technology company that makes the Mira at-home hormone monitor, which pairs disposable test wands with an AI-powered app to track LH, E3G, PdG and FSH for fertility, PCOS and perimenopause.
About
Mira (Quanovate Tech Inc.) is a US women's health technology company that makes the Mira at-home hormone monitor, which pairs disposable test wands with an AI-powered app to track LH, E3G, PdG and FSH for fertility, PCOS and perimenopause. It is FDA-registered and Health Canada licensed, with users in 40+ countries.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Mira
Mira (Quanovate Tech Inc.) is a US women's health technology company that makes the Mira at-home hormone monitor, which pairs disposable test wands with an AI-powered app to track LH, E3G, PdG and FSH for fertility, PCOS and perimenopause. It is FDA-registered and Health Canada licensed, with users in 40+ countries.
$5M
$5M
United States
BusinessLatest roundTotal raisedDate- Clair Health
Noninvasive continuous hormone-monitoring wearable and companion app for women, using machine learning to infer hormone levels from biosensor data
$12M
$12M - Aurenar
V-Link, a non-invasive, single-use neuromodulation platform that uses low-energy transcutaneous auricular vagus nerve stimulation via the outer ear to modulate inflammation and reduce fatal complications in ICU patients; first indication is cerebral vasospasm after aneurysmal subarachnoid hemorrhage; FDA Breakthrough Device designation
Seed · $6M · 2026-07
$6M - Function
Membership-based personal health testing platform (annual fee starting at about $365), offering more than 160 laboratory blood tests plus MRI/CT imaging and AI health interpretation.
Strategic · $450M · 2026-07 · Valuation $2.5B
$450MValuation $2.5B
China
BusinessLatest roundTotal raisedDate- 睿心医疗
Developer of AI precision diagnosis and treatment platforms for cardiovascular and cerebrovascular disease and of vascular interventional surgical robots.
Strategic · 2026-07
— - Xensur Medical
AR simulation training and AI surgical data analysis system for cataract surgery, for ophthalmology resident training
— - DeepInformatics++
AI + digital pathology focused on core diagnostic needs: full-chain digital pathology department solutions incl. smart scanning, QC and multi-cancer analysis; develops the DeepPathAI pathology model.
Series C · 2026-07
—
Europe
BusinessLatest roundTotal raisedDate- Implicity
Data aggregation and AI risk alert platform for remote monitoring of cardiac implantable electronic devices (CIEDs)
Undisclosed · 2026-09
— - Oxford Cancer Analytics
AI-based blood tests for cancer detection
Series A · $11M · 2025-01
$11M - Holifya
AI-driven digital obesity clinic with personalized GLP-1 weight-loss treatment management
$3M · 2026-09
$3M
Other / unspecified
BusinessLatest roundTotal raisedDate- HoneyNaps
Uses advanced algorithms to analyze sleep data and provide accurate diagnostic insights
Series B · $12M · 2024-05
$12M - Cent
Annual preventive health check protocol for consumers: whole-body MRI, low-dose CT, DEXA, ECG/ultrasound and 100+ blood and urine biomarkers, with an in-house AI system synthesizing multimodal imaging and biomarker data into health scores and risk ratings; runs its own clinical prevention centers in Bengaluru, Mumbai and Delhi NCR, and works with Siemens Healthineers to shorten scan times.
$5M
$5M - Medmain
AI-based cloud platform for digital pathology analysis and remote diagnosis; develops and offers PidPort, an AI-driven cloud system for digital pathology
Undisclosed · $3M · 2025-05
$3M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.